News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Quark Pharmaceuticals Inc. Announces First Patient Dosed In A Phase 2a Trial Evaluating QPI-1007 For Neuroprotection In Patients With Acute Primary Angle Closure Glaucoma



6/25/2014 9:15:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FREMONT, Calif., June 25, 2014 (GLOBE NEWSWIRE) -- Quark Pharmaceuticals, Inc. today announced that the first patient has been dosed in a double-masked, randomized sham controlled Phase IIa safety, tolerability and pharmacokinetics study of Quark's proprietary neuroprotective agent QPI-1007 when administered by single intravitreal (IVT) injection in patients suffering an acute attack of primary angle closure glaucoma (PACG). QPI-1007 is a siRNA designed to temporarily inhibit the expression of Caspase 2, a protein that has been shown to play a role in retinal ganglion cell (RGC) cell death. QPI-1007 is currently under investigation for the treatment of non-arteritic ischemic optic neuropathy (NAION). In a Phase I/IIa multicenter clinical study recently completed in the USA and Israel a single intravitreal injection of QPI-1007 resulted in a neuroprotective effect in NAION patients.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Glaucoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES